Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003820priorityCriticalpatent/ECSP003820A/en
Publication of ECSP003820ApublicationCriticalpatent/ECSP003820A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente invención se refiere a una combinación de un primer agente que incluye un agonista o antagonista del receptor de 5-HT4, o un antagonista del receptor de 5-HT3 y un coagente, y a composiciones y formulaciones farmacéuticas que contienen la combinación. La combinación farmacéutica se puede emplear para el tratamiento de movilidad gastrointestinal alterada, sensibilidad, secreción o desórdenes abdominales. La dosificación de preferencia es oral, y la administración de preferencia es una o dos veces al día. El primer agente preferido es tegaserod.The present invention relates to a combination of a first agent that includes a 5-HT4 receptor agonist or antagonist, or a 5-HT3 receptor antagonist and a coagent, and to pharmaceutical compositions and formulations containing the combination. The pharmaceutical combination can be used for the treatment of altered gastrointestinal mobility, tenderness, secretion or abdominal disorders. The dosage of preference is oral, and the administration of preference is once or twice a day. The first preferred agent is tegaserod.
ECSP0038202000-12-082000-12-08
PHARMACEUTICAL COMBINATIONS AND THEIR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS
ECSP003820A
(en)
Combination of a transdermal therapeutic system and an oral and / or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseases
Use of at least one compound selected from melatonin, melatoninergic agents, melatonin agonists and antagonists, in an amount of 0.0025-50 mg, to prepare a useful medicine for the treatment and improvement of the restorative quality of sleep.